Fox Chase Cancer Center’s Elizabeth Plimack Appointed Medical Oncology Editor for European Urology Journal

Dr. Elizabeth Plimack, chief of the Division of Genitourinary Medical Oncology, appointed medical oncology editor for the journal European Urology.

PHILADELPHIA (June 21, 2021)—Elizabeth Plimack, MD, MS, chief of the Division of Genitourinary Medical Oncology and professor in the Department of Hematology/Oncology at Fox Chase Cancer Center, was recently appointed medical oncology editor for the journal European Urology.

“It’s great to be able to bring multidisciplinary research to the forefront through this journal, which has a strong impact factor, a streamlined process for rapidly reviewing papers, and has been a reliable forum for publishing practice-changing findings,” said Plimack.

European Urology is the official journal of the European Association of Urology and seeks to improve the care of individuals with urological diseases, according to its mission statement. The monthly publication is read by more than 20,000 urologists worldwide and has been recognized as a prestigious journal for 35 years. Before becoming the medical oncology editor, Plimack submitted work to European Urology for several years and has worked with them as a reviewer.

European Urology has skyrocketed to prominence in the urology, radiation oncology, and medical oncology fields. While it’s a urology journal, it’s really expanded into all those areas,” she said.

Plimack directs genitourinary clinical research at Fox Chase. The research looks at identifying biomarkers in neoadjuvant cisplatin-based chemotherapy in bladder cancer, as well as developmental therapeutics and immunotherapy in genitourinary malignancies. She specializes in the treatment of kidney, bladder, and prostate cancer, and runs a clinical practice focused on these diseases.

In addition to her other roles, Plimack is an elected member of the Board of Directors of the American Society of Clinical Oncology and an advisor to the Society of Urologic Oncology Clinical Trials Consortium. She was recently appointed chair of the scientific advisory board for the Bladder Cancer Advocacy Network and serves on multiple clinical trial steering and safety monitoring committees.

Plimack is also a member of the National Comprehensive Cancer Network guidelines panels for prostate, kidney, and bladder/penile cancers. She was also recently recognized as a 2021 Top Doctor by Philadelphia magazine.

“The field of research in patient care is international. I’m especially proud to be part of this effort bringing expertise from around the world to bear on issues important to the treatment of these cancers,” said Plimack.

Fox Chase Cancer Center (Fox Chase), which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health, is one of the leading comprehensive cancer centers in the United States. Founded in 1904 in Philadelphia as one of the nation’s first cancer hospitals, Fox Chase was also among the first institutions to be designated a National Cancer Institute Comprehensive Cancer Center in 1974. Fox Chase is also one of just 10 members of the Alliance of Dedicated Cancer Centers. Fox Chase researchers have won the highest awards in their fields, including two Nobel Prizes. Fox Chase physicians are also routinely recognized in national rankings, and the Center’s nursing program has received the Magnet recognition for excellence six consecutive times. Today, Fox Chase conducts a broad array of nationally competitive basic, translational, and clinical research, with special programs in cancer prevention, detection, survivorship, and community outreach. It is the policy of Fox Chase Cancer Center that there shall be no exclusion from, or participation in, and no one denied the benefits of, the delivery of quality medical care on the basis of race, ethnicity, religion, sexual orientation, gender, gender identity/expression, disability, age, ancestry, color, national origin, physical ability, level of education, or source of payment.

For more information, call 888-369-2427